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2ABSTRACT 
The presence of autoantibodies to multiple islet autoantigens confers high risk for 
development of Type 1 diabetes. Four major autoantigens are established (insulin, 
glutamate decarboxylase, IA-2, and zinc transporter-8), but the molecular identity of a 
fifth, a 38kDa membrane glycoprotein (Glima), is unknown. Glima antibodies have been 
detectable only by immunoprecipitation from extracts of radiolabeled islet or neuronal 
cells. We sought to identify Glima to enable efficient assay of these autoantibodies. 
Mouse brain and lung were shown to express Glima.  Membrane glycoproteins from 
extracts of these organs were enriched by detergent phase separation, lectin affinity 
chromatography and SDS-PAGE. Proteins were also immunoaffinity purified from brain 
extracts using autoantibodies from diabetic patients’ sera before SDS-PAGE. Eluates 
from gel regions equivalent to 38kDa were analyzed by LC-MS/MS for protein 
identification. Three proteins were detected in samples from the brain and lung extracts, 
and in the immunoaffinity purified sample, but not the negative control. Only tetraspanin-
7, a multipass transmembrane glycoprotein with neuroendocrine expression, had physical 
characteristics expected of Glima. Tetraspanin-7 was confirmed as an autoantigen by 
demonstrating binding to autoantibodies in Type 1 diabetes.  We identify tetraspanin-7 as 
a target of autoimmunity in diabetes, allowing its exploitation for diabetes prediction and 
immunotherapy. 
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3INTRODUCTION 
Detection of circulating autoantibodies to pancreatic islets (1), and identification of their 
molecular targets (2), has allowed development of high throughput autoantibody assays 
for clinical diagnosis of Type 1 diabetes and identification of individuals at risk for 
disease. Evidence from both animal studies and human trials indicate that Type 1 diabetes 
may be prevented in individuals at risk (3; 4). Hence, a range of therapies to interfere 
with immune responses has proved effective in preventing disease development in animal 
models of diabetes (5)  and in slowing the loss of beta cell function occurring in the 
months following disease diagnosis in man (6-8). There is now a focus on development 
of procedures to interfere specifically in immune responses that cause Type 1 diabetes, 
requiring knowledge of the major targets of the autoimmune response. There is no single 
common autoimmune target and individuals differ in antigen specificity of autoimmune 
responses they develop. Four major humoral autoantigens have been identified in Type 1 
diabetes by defining the specificity of autoantibodies in the disease: insulin (9), glutamate 
decarboxylase (10), IA-2 (11), and zinc transporter-8 (ZnT8) (12). Autoantibodies to a 
fifth, a 38kDa glycosylated membrane protein (Glima), have been detected in 19-38% of 
Type 1 diabetic patients, with significantly higher prevalence (up to 50%) in children (13-
15). The molecular identity of Glima has for many years proved elusive, hampering the 
characterization of autoimmunity to the protein and the development of sensitive, specific 
autoantibody assays. Glima is expressed in pancreatic beta and neuronal cell lines, is 
hydrophobic, heavily N-glycosylated, having affinity for the lectin wheat germ 
agglutinin, and has a core protein backbone of approximately 22kDa (13-15). The aim of 
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this study was to take advantage of these known physical properties to prepare Glima- 
enriched extracts for identification of the autoantigen by mass spectrometry.  
RESEARCH DESIGN AND METHODS 
Patients.  Serum samples were obtained from 40 Type 1 diabetic patients (12- 6 y) 
within 6 months of diagnosis from clinics in West Yorkshire with informed consent for 
screening for high-titer Glima antibodies, 94 additional patients (12-63 y) for assay 
verification and 52 non-diabetic individuals as negative controls. Approval for analysis of 
autoantibodies in sera from these individuals was obtained from the Yorkshire and the 
Humber – Bradford Leeds Research Ethics Committee. 
Screen of type 1 diabetic patient sera for Glima antibodies.  Glima antibodies were 
detected by a modification of immunoprecipitation assays previously described (13-15) 
using the neuronal mouse cell line GT1.7 as source of antigen. Endogenous proteins in 
GT1.7 cells were labeled by incubation in methionine-free DMEM medium containing 4 
MBq/ml
 35
S-methionine for 7 h at 37°C. Cells were washed with Hepes buffer (10 mM 
Hepes, pH 7.4, 150 mM NaCl, 10 mM benzamidine) and stored at -80°C. Frozen cell 
pellets were extracted in Hepes buffer containing 2% Triton X-100 for 2 h on ice and 
insoluble material removed by centrifugation at 15,000 g for 15 min at 4°C. Membrane 
glycoproteins were isolated by incubating cell extracts with wheat germ agglutinin- 
agarose on ice for 30 min and, after washing in Hepes buffer containing 0.5 mM 
methionine, 100 mg/l bovine serum albumin and 0.5% Triton X-100, eluted in the same 
buffer containing 0.5 M N-acetyl glucosamine. Aliquots (20 µl) of eluate containing 3 × 
4
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5 
cpm of radiolabeled protein were incubated with 5 µl of test sera for 18 hours at 4°C
and immune complexes captured on 5 µl of protein A-Sepharose. Immunoprecipitated 
proteins were eluted in 15 µl of SDS-PAGE Loading Buffer (Novex, Life Technologies, 
Paisley, UK) with heating at 90°C for 5 min and subjected to SDS-PAGE on 12% 
polyacrylamide gels. After electrophoresis, gels were incubated in 40% v/v methanol, 
2.5% v/v acetic acid and subsequently in Enlightning autoradiographic enhancer (Perkin-
Elmer, Coventry, UK), each for 30 min. Gels were dried and contacted with X-ray film 
(BioMax MR film; Kodak, Watford, UK) for up to two weeks. After exposure, X-ray 
film was developed to detect radiolabeled proteins specifically immunoprecipitated by 
sera from Type 1 diabetic patients, with bands detected in the 38,000 relative molecular 
mass (Mr) region indicating positivity for Glima antibodies.  
Tissue expression screen. To identify mouse organs containing highest levels of Glima 
for use in antigen purification, competitive binding studies were performed using 
detergent extracts of organs as unlabeled competitors with 
35
S-methionine-labeled Glima
for binding to Glima antibodies in serum from a high-titer Glima antibody positive 
patient.  Mouse kidney, brain, heart, liver, thyroid, muscle, salivary gland, thymus, 
pancreas, spleen, adrenal, pituitary, and lung were dissected, frozen in liquid nitrogen and 
stored at -80°C before extraction. Tissues were homogenized in homogenization buffer 
(10 mM Hepes, pH 7.4, 0.25 M sucrose, 10 mM benzamidine), and membrane fractions 
sedimented by centrifugation at 15,000 g for 30 min at 4°C. Supernatants were removed 
and pellets extracted in 2% Triton X-100 extraction buffer for 2 h on ice. Extracts were 
centrifuged at 15,000 g for 30 min at 4°C and supernatants collected. The protein 
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6concentrations of extracts were determined using the Pierce BCA protein assay kit 
(Thermo Fisher Scientific, Loughborough, UK).   
For the competition assay, wheat germ agglutinin agarose eluates from extracts of 
35
S-
methionine-labeled GT1.7 cells were prepared as described above. Aliquots (20 µl) of 
GT1.7 cell glycoproteins containing 3 × 10
5
 cpm of radiolabeled proteins were incubated
for 18 h at 4°C with 5 µl of serum from patient 029 alone, or with 10 µl of detergent 
extracts containing 100 µg of extracted protein from each mouse tissue. Immune 
complexes were captured on protein A-Sepharose and processed for SDS-PAGE and 
autoradiography.   
Partial purification of Glima from mouse brain and lung.  Mouse brain and lung, 
shown to express Glima in the tissue screen (see Results), were homogenized in ice-cold 
homogenization buffer in a Dounce homogenizer and cell debris removed by 
centrifugation at 500 g for 5 min at 4°C. A membrane fraction was prepared by 
centrifugation of the supernatant at 10,000 g for 15 min at 4°C, and the pellet washed and 
extracted in 2% Triton X-114 extraction buffer for 2 h at 4°C. Insoluble material was 
removed by centrifugation at 10,000 g for 15 min at 4°C and a detergent phase prepared 
by heat-induced phase-separation as previously described (13). Fractions were added to 
wheat germ agglutinin-agarose at a ratio of 100 µl lectin-agarose to 5 mg total protein and 
incubated overnight at 4°C with gentle mixing. The beads were washed twice with Hepes 
buffer containing 0.5% Triton X-100 and twice in NOG buffer (1% n-octyl-
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7glucopyroside in Hepes buffer). Wheat germ agglutinin-binding proteins were eluted in 
0.5 M n-acetyl-glucosamine in NOG buffer.  
Eluates were concentrated using the SDS-PAGE Sample Preparation kit (Pierce, Life 
Technologies, Paisley, UK), solubilized in SDS-PAGE Loading Buffer (Novex, Life 
Technologies) for 10 minutes at 60°C and electrophoresed on 12% Bis-Tris gels in 
MOPS running buffer. Gels were stained with Brilliant Blue G-Colloidal Coomassie 
(Sigma-Aldrich, Poole, UK) and gel slices corresponding to the 38,000 Mr region excised 
for mass spectrometry. 
Immunoaffinity purification with Glima antibodies.  For immunoaffinity purification, 
250 µl of pooled sera from three patients with high Glima antibodies were used with 250 
µl sera from three antibody-negative individuals as negative control. Sera were incubated 
with Protein A-Sepharose (250 µl) for 1 h at room temperature with rolling and washed 
three times in borate buffer (100 mM boric acid, pH 8.3). Antibodies were cross-linked to 
Protein A-Sepharose with 20 mM dimethylpimelidate in borate buffer for 1 h.  Unreacted 
sites were blocked with 20 mM ethanolamine for 10 min and washed before use.  
Triton X-114 detergent phase-purified amphiphilic proteins from mouse brains prepared 
as above were added to the Glima antibody-positive and -negative beads and incubated 
overnight at 4°C with mixing. Beads were washed with 0.5% Triton X-100 in Hepes 
buffer prior to elution in 2% SDS at 90°C for 10 min. The eluate was concentrated to 20 
µl using the SDS-PAGE Sample Preparation Kit, subjected to SDS-PAGE and Colloidal 
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8Coomassie gel staining as above, and gel slices in the 38,000 Mr region excised for mass 
spectrometry. 
In-gel trypsin digestion and mass spectrometry of 38,000 Mr proteins.  Gel slices 
representing 38,000 Mr regions of all samples were processed using the In-Gel Tryptic 
Digestion kit (Pierce) according to the manufacturer’s instructions and the trypsin-treated 
extracts vacuum-dried and stored at -20°C prior to mass spectrometry. Samples were 
reconstituted in 30 µl of 50 mM ammonium bicarbonate for 30 min at room temperature 
and centrifuged at 15,000 g for 15 min to remove insoluble material. Samples were 
transferred to autosampler tubes and 10 µl of each analyzed by LC-MS/MS. Peptides 
were resolved by reversed phase chromatography on a 75 µm C18 EASY column using a 
linear gradient of acetonitrile in 0.1% formic acid at a flow rate of 300 nL/min over 50 
min on an EASY Nano LC system (Thermo Fisher Scientific). The eluate was ionized by 
electrospray ionization using an Orbitrap Velos Pro machine (Thermo Fisher Scientific) 
operating under Xcalibur (version 2.2; Thermo Fisher Scientific) and precursor ions 
selected based on their intensity for sequencing by collision-induced fragmentation. The 
MS/MS analyses were conducted using collision energy profiles that were chosen based 
on the mass-to-charge ratio (m/z) and the charge state of the peptide. 
Tandem mass spectra were processed into peak lists using Proteome Discoverer (version 
1.3; Thermo Fisher Scientific). All MS/MS samples were analyzed using Mascot (version 
2.2.06; Matrix Science, London, UK) searching the Uniprot Mus musculus database, 
assuming digestion with trypsin. Mascot was searched with a fragment ion mass 
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9tolerance of 0.80 Da and a parent ion tolerance of 10.0 PPM, with oxidation of 
methionine and carbamidomethylation of cysteine as variable modifications. Each dataset 
was analyzed with a reverse FASTA database acting as a decoy. 
Scaffold (version 4.3.2; Proteome Software Inc., Portland, OR) was used to validate 
MS/MS based peptide and protein identifications, which were assigned by Peptide 
Prophet algorithms (16; 17) and accepted at > 95.0% probability. The UniProt database 
was manually searched for physical characteristics of the proteins identified, including 
molecular weight, tissue distribution, and glycosylation. Of those identified, only one, 
tetraspanin-7 (Tspan7), matched the known properties of Glima (see Results) and was 
characterized further. 
Immunohistochemistry.  Tspan7 localization in rodent tissues was performed by 
immunohistochemistry. Sections of formalin-fixed paraffin-embedded rat brain, pituitary, 
pancreas, adrenal gland, lung, muscle, heart, liver, kidney, spleen, and thymus were de-
waxed and subjected to epitope retrieval in a microwave pressure cooker in 10 mM citric 
acid pH 6.0, 0.05% Tween 20. Endogenous peroxidase activity was inhibited with 0.3% 
H2O2 and non-specific binding blocked with 25% non-immune swine serum in PBS. 
Primary antibody to Tspan7 (Anti-TM4SF2, Sigma-Aldrich; HPA003140) was applied at 
1:1,000 dilution and incubated overnight at 4°C. Antibody labeling was detected with the 
Envision kit (Dako, Ely, UK) according to the manufacturer’s instructions, sections 
counterstained in Meyers Haematoxylin (Sigma-Aldrich) and visualized by microscopy. 
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Cloning and expression of recombinant Tspan7.  cDNA for the coding region of 
mouse Tspan7 was amplified by RT-PCR from the mouse islet cell line Min6 using 
primers (5ʹ- GAATTCATGGCATCGAGGAGAATGG-3ʹ and 5ʹ- 
AGATCTCACCATCTCATACTGATTGGC-3ʹ) that introduce EcoR1 and BglII sites at 
the 5ʹ and 3ʹ ends, respectively, with the native stop codon removed to allow expression 
as a fusion protein with a C-terminal purification tag. The PCR product was cloned into 
the pFLAG-CTS expression vector for protein expression in E. coli BL21 cells after 
induction with IPTG. Expressed protein was extracted from cells with Hen Egg 
Lysozyme (1 mg/ml) in PBS containing 10 mM benzamidine, 1 mM PMSF for 30 min at 
room temperature, followed by incubation in Triton X-100 (0.1%) for 5 min and DNase 
(1 µg/ml) for 10 min. The lysate was centrifuged at 10,000 × g for 10 min at 4°C, and the 
supernatant used in immunoprecipitation assays.  
Tspan7 binding to autoantibodies in Type 1 diabetes.  Individual Glima antibody- 
positive and -negative human sera (15 µl) were incubated with protein A-Sepharose (15 
µl), and the immunoglobulin captured was cross-linked to beads with dimethyl 
pimelimidate (18). Bead-bound antibodies were incubated overnight at 4°C with Triton 
X-100 extracts of mouse brain, or with lysates of E. coli expressing recombinant mouse 
Tspan7. Beads were washed three times in 0.5% Triton X-100 in Hepes buffer and 
captured proteins subjected to SDS-PAGE and Western blotting using rabbit anti-Tspan7 
antibody (anti-TM4SF; Sigma-Aldrich HPA003140) at 1:250 dilution overnight at 4°C. 
Immunoprecipitated Tspan7 was detected with goat anti-rabbit IgG-peroxidase (product 
10
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A0545; Sigma-Aldrich;) and SuperSignal West Pico Chemiluminescent substrate 
(Thermo Fisher Scientific). 
Luminescent immunoprecipitation assay for detection of Tspan7 antibodies 
The coding region of human Tspan7 was cloned into the pCMVTnT vector as a fusion 
with Nanoluciferase (Promega, Southampton, UK) at the 3’ end.  The construct was 
transfected into HEK 293 cells with ExpiFectamine (Thermo Fisher Scientific) for 
transient expression of antigen.  Transfected cells were extracted in either 2% Triton-
X114 or passive lysis buffer (Promega) and insoluble material removed by centrifugation. 
Triton-X-114 extracts were subjected to phase separation as described above and 
analysed for fusion protein by Western blotting with rabbit antibodies to Nanoluciferase 
(gift of Promega UK), or Tspan7 (anti-TM4SF).  Luciferase expression in the cell 
extracts was quantified by luminometry using Nano-Glo assay reagent (Promega) and 
aliquots of passive lysis buffer extracts containing 10
6
 light units of antigen were
incubated with 5 µl of serum at 4°C for 16 h prior to capture of antibody complexes on 
protein A Sepharose.  Mouse brain extracts (150 µg protein) or lysates of E coli 
expressing Tspan7 (250 µg protein) were added to reactions as sources of Tspan7 to 
compete for antibody binding.  Complexes were washed and luciferase activity 
immunoprecipitated determined by luminometry with Nano-Glo assay reagent. 
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RESULTS 
Selection of Glima antibody-positive sera.  To identify patients with high levels of 
Glima antibodies for immunoaffinity purification, sera from 40 recent-onset Type 1 
diabetic patients were screened by immunoprecipitation using radiolabelled mouse GT1.7 
cell extracts (Fig 1). Intense diffuse 38,000 Mr bands typical of Glima were detected for 
three patients, indicative of high levels of Glima antibodies (029, 037 and 110 in Fig. 1). 
These three sera were used for subsequent Glima characterization and purification. 
Weaker 38,000 Mr bands indicative of Glima antibody positivity were detected in an 
additional 11 patients (Fig 1). 
Tissue specificity of Glima expression.  To identify large organs in which Glima is 
expressed at suitably high levels for antigen purification, competitive binding studies 
were performed in which detergent extracts of normal mouse tissues acted as unlabeled 
competitors with radiolabeled Glima from GT1.7 cell lysates for binding to antibodies in 
serum from the strong Glima antibody-positive patient, 029. Extracts of brain, pituitary, 
and lung reduced the intensity of radiolabeled 38,000 Mr protein, indicative of Glima 
immunoreactivity in these tissues (Fig. 2).  
Identification of Glima candidate proteins by mass spectrometry. Extracts enriched 
for glycosylated membrane proteins from both brain and lung were prepared using Triton 
X-114 phase separation of amphiphilic membrane proteins followed by wheat germ
agglutinin affinity purification. Proteins migrating at 38,000 Mr by SDS-PAGE were 
12
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trypsinized and analyzed by LC-MS/MS. A total of 65 candidates in brain and 25 in lung 
were identified, of which 20 were common to both samples, (Supplementary Table 1). 
Glycosylated membrane proteins immunoprecipitated from brain extracts by antibodies 
in the high Glima antibody titer patients’ serum pool were also subjected to SDS-PAGE 
and LC-MS/MS analysis and three of the 20 protein candidates common to brain and 
lung were present in the Glima antibody-positive sample, but not the negative control 
(Supplementary Table 1). These were: 1) cytoplasmic actin-1 (Actb), a ubiquitous non-
glycosylated cytoskeletal protein with a predicted molecular weight of 42 kDa; 2) 
guanine nucleotide-binding protein G(i) subunit alpha-2 (Gnai2), a non-glycosylated 
membrane associated 40 kDa protein with a wide tissue distribution; and 3) tetraspanin-7 
(Tspan7), a hydrophobic four-transmembrane domain protein with core molecular weight 
27.5 kDa, five putative N-glycosylation sites and a neuroendocrine distribution. Tspan7 
closely matched the known properties of Glima and additional studies were performed to 
compare properties and validate Tspan7 as the autoantigen. 
Localization of Tspan7 in rat tissues.  The tissue distribution of Tspan7 was determined 
by immunohistochemistry for comparison with patterns of Glima expression in 
competition experiments above. Strong immunolabeling for Tspan7 was detected in the 
rat brain, in particular the cerebral cortex, hippocampus, cerebellum, striatum and 
thalamus (Fig. 3A), in the pancreatic islets (Fig. 3B), in the anterior pituitary (Fig. 3C), 
and in epithelial cells lining the alveoli in the lung (Fig. 3D). These observations agree 
with the Glima immunoreactivity described above, and previously (13, 15). Weak Tspan7 
immunolabelling was also found in cells of the adrenal gland (Fig. 3E). No evidence of 
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Tspan7 expression was found in the exocrine pancreas (Fig. 3B), muscle, heart, liver, 
kidney, spleen, or thymus (not shown). 
Immunoprecipitation of Tspan7 by antibodies in Type 1 diabetes.  To demonstrate 
that Tspan7 is a target for autoantibodies in Type 1 diabetes, extracts of mouse brain and 
lysates of E. coli expressing recombinant mouse Tspan7 were subject to 
immunoprecipitation with Glima antibody-positive and -negative sera followed by 
Western blotting with a rabbit antibody to Tspan7. A 38,000 Mr band representing 
Tspan7 was selectively immunoprecipitated from mouse brain detergent extract by three 
Glima antibody-positive sera, but not by control samples. The bands detected co- 
migrated with the brain lysate control (Fig. 4A). Antibodies in Type 1 diabetic patients’ 
sera also specifically immunoprecipitated Tspan7 from bacterial lysates containing 
recombinant protein (Fig 4B). Here, the protein migrated at approximately 22,000 Mr, 
consistent with a lack of glycosylation in bacteria (Fig. 4B). The results confirm Tspan7 
as a target of autoantibodies in Type 1 diabetes. 
Analysis of Tspan7 antibodies by luminescence immunoprecipitation assay 
Patients screened for Glima antibodies were analyzed for Tspan antibodies by 
immunoprecipitation of recombinant Nanoluciferase-tagged human Tspan7. Western 
blotting with rabbit polyclonal antibodies to both Nanolucoferase and Tspan7 detected 
diffuse 38,000 Mr bands (the expected size of the non-glycosylated fusion protein) as the 
dominant immunoreactivity in cells transfected with the construct, with additional bands 
at approximately 80,000 Mr (Fig 4C). The 38,000 Mr protein partitioned into the 
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detergent on temperature-induced phase separation in Triton X-114. Transfected cell 
extracts were used in immunoprecipitation studies with normal control sera or with sera 
from Glima antibody-positive and -negative Type 1 diabetic patients. All but one (V015) 
of the controls (n=52) had low Tspan7 antibodies (Fig 4D). Four patients with high 
Glima antibodies (Fig 1) also immunoprecipitated high luciferase activity in the Tspan7 
antibody assay (Fig 4D) and significantly higher levels of Tspan7 antibodies were found 
in Glima antibody-positive patients than those Glima antibody negative (p<0.0001; Mann 
Whitney U test). In competition assays, natural or recombinant Tspan7 in brain or E coli 
extracts partially (control sample V015), or completely (Glima antibody positive Type 1 
diabetic patients) blocked antibody binding to the Nanoluciferase-Tspan7 construct (Fig 
4E).  Control V015 did not bind Tspan7 from mouse brain extracts when tested in the 
Western blotting assay. A second set of 94 recent onset Type 1 diabetic patients were also 
tested in the Tspan7 antibody assay.  Using a cut-off of mean + 3SD of controls (omitting 
the outlier), 40 (43%) were positive for Tspan7 antibodies (Fig 4D). 
15
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DISCUSSION 
Autoantibodies to “Glima” in Type 1 diabetes were first reported in 1996 (13), but its 
molecular identity has since then remained unknown. We used mass spectrometry of 
Glima-enriched fractions of brain and lung to search for likely candidates for Glima. LC-
MS/MS analysis identified 65 proteins in 38,000 Mr gel samples of amphiphilic 
membrane glycoproteins from brain and 25 from lung, of which 20 were common to both 
(Supplementary Table 1).  Additional LC-MS/MS analysis of immunoaffinity-purified 
proteins isolated from brain extracts using protein A Sepharose-coupled 
immunoglobulins from Glima antibody-positive sera (with similar preparations from 
Glima antibody-negative sera as a negative control) further narrowed down potential 
candidates for testing of autoantigenicity.  Only six proteins detected in the brain or lung 
extracts were also present in the immunoaffinity purified sample but absent in the 
negative control. Of these, five (Actb, Gnai2, Sfxn5, Kctd12 and Tuba1b) had 
considerably higher predicted molecular weight (>36kDa) than expected for the non-
glycosylated Glima protein (approximately 22kDa; reference 15).  Furthermore, Actb, 
Gnai2 and Tub1a are ubiquitous cytoplasmic proteins lacking the amphiphilic 
characteristics expected of Glima.  Sfxn5 and Kctd12 were not detected in the lung 
extract. Tspan7 was consequently the most promising candidate for Glima identified in 
the LS-MS/MS analyses. 
Tspan7 is a member of the tetraspanin family, members of which share structural 
characteristics of four transmembrane domains, with one short (EC1) and one long (EC2) 
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extracellular loop (19). Four of the putative N-glycosylation sites are contained within the 
EC2 domain with a further site located in EC1. The presence of multiple transmembrane 
domains and N-glycosylation sites within Tspan7, is consistent with the hydrophobic 
properties and heavy N-glycosylation previously reported for Glima (13,15).  There are 
four amino acid differences between mouse and human Tspan7, all being located in the 
long extracellular loop.  The tissue distribution of Tspan7 expression has not been widely 
investigated but analysis of transcriptional activity of the Tspan7 gene has shown 
restricted tissue distribution with high levels being detected in regions of the adult mouse 
brain and lung (20).  In the pancreas, Tspan7 is found specifically in the islets of 
Langerhans (21).  Functionally, tetraspanin family members are involved in mediating 
signal transduction events and have been noted to regulate cell development, activation, 
growth, and motility through the trafficking of other transmembrane proteins (22). Both 
the extracellular and intracellular domains are able to interact with other proteins, and a 
number of tetraspanins bind integrins, thereby forming links with the actin cytoskeleton 
(23). Mutations in the Tpan7 gene are associated with X-linked mental retardation and 
neuropsychiatric diseases, potentially as a result of impaired ability of the actin 
cytoskeleton to drive neurite outgrowth (24). The ability of tetraspanins to form 
complexes with other membrane and cytosolic proteins may explain co-purification of 
multiple protein fragments identified in the LC-MS/MS analysis.   
Proteins immunoprecipitated by Glima antibody-positive sera from brain extracts, or 
from bacterial extracts containing recombinant Tspan7, also bound rabbit antibodies to 
Tspan7 by Western blotting, confirming Tspan7 as the target of the antibodies.  Glima 
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autoantibodies bound both the glycosylated natural 38,000 Mr Tspan7 in brain and the 
22,000 Mr non-glycosylated form of the protein expressed in E. coli. A luminescence- 
based immunoprecipitation system (LIPS; 25) using Nanoluciferase-tagged human 
Tspan7 expressed in mammalian cells showed that patients with high levels of Glima 
autoantibodies were also strongly positive in the anti-Tspan7 LIPS.  The relationship 
between Glima- and Tspan-autoreactivity is imperfect, which may in part be the 
consequence of difficulties in ascertaining whether or not diffuse Glima bands are present 
on autoradiographs of immunoprecipitation reactions (see Fig 1).  Non-diabetic 
individuals had low levels of Tspan7 antibodies, with the exception of one strongly 
positive control. Antibodies in this control serum bound poorly to natural Tspan7 from 
mouse brain extracts suggesting that antibodies in this particular sample may bind 
epitopes not displayed on the natural protein. The SDS-PAGE gel migration of the fusion 
protein indicated that the majority of recombinant luciferase-tagged protein was not 
subject to heavy glycosylation found on the natural protein, indicative of incorrect 
membrane insertion, protein folding or intracellular targeting of the fusion protein 
required for appropriate post-translational modification.  Incorrect folding or lack of 
glycosylation may reveal antibody epitopes not normally displayed on the natural 
Tspan7.  Further optimization of Tspan7 expression should permit the development of 
high throughput assays for the detection of diabetes-associated Tpan7 autoantibodies with 
high sensitivity and specificity. 
Autoimmunity to major autoantigens in Type 1 diabetes appears within the first five 
years of life in at-risk children (26), with individual immune responses developing 
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sequentially rather than simultaneously (27). Autoimmunity in the disease is therefore 
progressive, with the order of appearance of autoimmune responses to individual antigens 
differing between individuals, and diversification of the immune response being essential 
for disease progression; individuals who develop autoimmunity to only single 
autoantigens rarely develop disease (28). The optimum strategy currently adopted for 
assessing disease risk is to screen individuals for the presence of autoantibodies to 
multiple islet autoantigens. The inclusion of Tspan7 antibodies in the screen may 
improve sensitivity and specificity of disease prediction in large populations, and will 
provide a fuller description of the major autoimmune responses that are developing in 
that individual, necessary for guiding the selection of autoantigen-specific 
immunotherapeutics to prevent the disease. 
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Figure legends 
Figure 1. Autoradiogram showing a screen of serum samples from Type 1 diabetic 
patients for Glima antibodies by immunoprecipitation of the 38,000 Mr protein from 
extracts of GT1.7 cells with detection by SDS-PAGE and autoradiography. A normal 
control serum (-ve) and a Type 1 diabetic patient previously determined to be positive for 
Glima antibodies (SL) were included in the assay.  The location of Glima on the 
autoradiograph is marked.  An indication of whether the samples were determined to be 
negative (-) or positive (+) for Glima antibodies is shown under each lane of the figure. 
Figure 2. Autoradiograph of tissue expression screen demonstrating competition for 
Glima antibody binding to Glima antibody positive serum “029” by proteins in Triton X-
100 detergent (100 μg) extracts of normal mouse tissues. Serum from a non-diabetic 
individual was included as a negative control.  Reduced intensity of the 38,000 Mr band 
is indicative of Glima immunoreactivity in that tissue. 
Figure 3. Immunohistochemical analysis of Tspan7 expression in rat tissues. Sections of 
formalin fixed, paraffin-embedded rat tissues were labeled with rabbit antiserum to 
Tspan7 and labeling detected by a peroxidase/DAB-based system with positive labeling 
detected as brown staining under the microscope. Representative images of labeling of 
tissue sections of brain (A), pancreas (B), pituitary (C), lung (D), and adrenal (E) are 
shown. 
Figure 4. A. Tspan7 labeling of Western blots of mouse brain proteins 
immunoprecipitated by antibodies in sera from Glima antibody-negative and positive 
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recent onset Type 1 diabetic patients. The migration of molecular weight markers (10
-3
 x
Mr) on the gel and the localization of Tspan7-specific bands at 38,000 Mr are marked. B. 
Tspan7 labeling of Western blots of proteins from lysates of Tspan7-expressing E.coli 
immunoprecipitated by antibodies in sera from Glima antibody-negative and -positive 
recent onset Type 1 diabetic patients. The localization of Tspan7-specific bands at 
approximately 22,000 Mr is marked; migration of molecular weight markers as in A. In 
both panel A and B, IgG heavy chains (50,000 Mr), light chains (25,000 Mr) and cross-
linked immunoglobulin (>100,000 Mr) from all serum samples were also detected on the 
blot as a consequence of cross-reactivity with the peroxidase-conjugated anti-rabbit 
detection antibody. C. Tspan7 was expressed as a fusion protein with Nanoluciferase and 
Triton X114 extracts of cells were subject to heat-induced phase separation.  Detergent 
and aqueous phases were subject to SDS-PAGE and Western blotting with antibodies to 
Nanoluciferase (NanoLuc) or Tspan7.  The migration of molecular weight markers are 
shown (10
-3
 x Mr).  D.  Detergent extracts of Nanoluciferase were immunoprecipitated
with normal control sera (n=30), Glima antibody (Ab) positive Type 1 diabetic (T1D) 
patients’ sera (n=15) and Glima antibody-negative Type 1 diabetic patients’ sera and 
luciferase activity associated with each immunoprecipitate determined by luminometry.  
Data are plotted as luciferase activity immunoprecipitated in kilo light units (kLU) and 
sample codes for control or diabetic individuals with high levels of antibodies are shown. 
E. Samples from control individuals or Glima antibody-positive Type 1 diabetic patients
were tested for competitive binding by natural or recombinant Tspan7 in the LIPS by 
performing the immunoprecipitations in the absence (black bars) or presence of 150 µg of 
mouse brain extract (white bars) or 250 µg of lysates of E coli expressing recombinant 
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Tspan7 (hatched bars).  Assays were performed in triplicate.  Addition of brain and E coli 
lysate significantly blocked antibody binding for all samples (p<0.0001; ANOVAR with 
Dunnett’s correction for multiple comparisons), with the exception of control sample CH. 
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Supplementary Table 1: Proteins identified by LC-MS/MS analysis of 38 kD gel purified amphiphilic 
membrane proteins from mouse brain and lung and from immunoaffinity-purified proteins from brain 
extracts using bead-immobilised antibodies from Glima antibody positive or negative control sera. 
Samples in which the protein was identified by LC-MS/MS analysis of the 38 kDa gel slice are indicated 
in the table by “Yes”.  Proteins that were identified in the brain and lung extracts and in the Glima 
antibody purified sample, but not the negative control are highlighted in bold.  
Identified Protein Accession 
Number 
Molecular 
Weight 
Brain 
extract 
Lung 
extract 
Antibody 
Purified 
Negative 
control 
Actin, cytoplasmic 1 (Actb) P60710 42 kDa Yes Yes Yes 
Guanine nucleotide-binding 
protein G(i) subunit alpha-2 
(Gnai2) 
P08752 40 kDa Yes Yes Yes 
Tetraspanin-7 (Tspan7) Q62283 28 kDa Yes Yes Yes 
Keratin, type I cytoskeletal 10 
(Krt10) 
P02535 58 kDa Yes Yes Yes Yes 
Keratin, type II cytoskeletal 1 (Krt1) P04104 66 kDa Yes Yes Yes Yes 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-1 
(Gnb1) 
P62874 37 kDa Yes Yes Yes Yes 
Keratin, type II cytoskeletal 5 (Krt5) Q922U2 62 kDa Yes Yes Yes Yes 
Voltage-dependent anion-selective 
channel protein 2 (Vdac2) 
Q60930 32 kDa Yes Yes Yes Yes 
Aquaporin-1 (Aqp1) Q02013 29 kDa Yes Yes 
Sideroflexin-3 (Sfxn3) Q91V61 35 kDa Yes Yes 
Sodium/potassium-transporting 
ATPase subunit beta-1 (Atp1b1) 
P14094 35 kDa Yes Yes 
Vesicular integral-membrane protein 
VIP36 (Lman2) 
Q9DBH5 40 kDa Yes Yes 
Sideroflexin-1 (Sfxn1) Q99JR1 36 kDa Yes Yes 
Phosphate carrier protein, 
mitochondrial (Slc25a3) 
Q8VEM8 40 kDa Yes Yes 
Guanine nucleotide-binding protein 
G(I)/G(S)/G(T) subunit beta-2 
(Gnb2) 
P62880 37 kDa Yes Yes 
Basigin (Bsg) P18572 42 kDa Yes Yes 
ER membrane protein complex 
subunit 2 (Emc2) 
Q9CRD2 35 kDa Yes Yes 
Ephrin-B2 (Efnb2) P52800 37 kDa Yes Yes 
Prohibitin-2 (Phb2) O35129 33 kDa Yes Yes Yes 
Keratin, type II cytoskeletal 2 
epidermal (Krt2) 
Q3TTY5 71 kDa Yes Yes Yes 
Sideroflexin-5 (Sfxn5) Q925N0 37 kDa Yes Yes 
BTB/POZ domain-containing protein 
KCTD12 (Kctd12) 
Q6WVG3 36 kDa Yes Yes 
Tubulin alpha-1B chain (Tuba1b) P05213 50 kDa Yes Yes 
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Guanine nucleotide-binding protein 
G(o) subunit alpha (Gnao1) 
P18872 40 kDa Yes Yes Yes 
Glyceraldehyde-3-phosphate 
dehydrogenase (Gapdh) 
P16858 36 kDa Yes Yes Yes 
Mitochondrial glutamate carrier 1 
(Slc25a22) 
Q9D6M3 35 kDa Yes Yes Yes 
Synaptophysin (Syp) Q62277 34 kDa Yes Yes Yes 
Sodium/potassium-transporting 
ATPase subunit alpha-3 (Atp1a3) 
Q6PIC6 112 kDa Yes 
Voltage-dependent calcium channel 
subunit alpha-2/delta-1 (Cacna2d1) 
O08532 125 kDa Yes 
Myelin proteolipid protein (Plp1) P60202 30 kDa Yes 
Sodium/potassium-transporting 
ATPase subunit alpha-2 (Atp1a2) 
Q6PIE5 112 kDa Yes 
NADH dehydrogenase [ubiquinone] 
1 alpha subcomplex subunit 9, 
mitochondrial (Ndufa9) 
Q9DC69 43 kDa Yes 
Sodium channel subunit beta-2 
(Scn2b) 
Q56A07 24 kDa Yes 
Major prion protein (Prnp) P04925 28 kDa Yes 
Repulsive guidance molecule A 
(Rgma) 
Q6PCX7 50 kDa Yes 
Sodium/potassium-transporting 
ATPase subunit alpha-1 (Atp1a1) 
Q8VDN2 113 kDa Yes 
Coxsackievirus and adenovirus 
receptor homolog (Cxadr) 
P97792 40 kDa Yes 
Ras-related protein Rab-3A (Rab3a) P63011 25 kDa Yes 
Electrogenic sodium bicarbonate 
cotransporter 1 (Slc4a4) 
O88343 121 kDa Yes 
Sodium channel subunit beta-1 
(Scn1b) 
P97952 25 kDa Yes 
Immunoglobulin superfamily 
member 21 (Igsf21) 
Q7TNR6 52 kDa Yes 
Ras-related protein Rab-10 (Rab10) P61027 23 kDa Yes 
Claudin-11 (Cldn11) Q60771 22 kDa Yes 
ADP/ATP translocase 1 (Slc25a4) P48962 33 kDa Yes 
Electron transfer flavoprotein subunit 
alpha, mitochondrial (Etfa) 
Q99LC5 35 kDa Yes 
Junctional adhesion molecule C 
(Jam3) 
Q9D8B7 35 kDa Yes 
Plasma membrane calcium-
transporting ATPase 2 (Atp2b2) 
Q9R0K7 133 kDa Yes 
Metaxin-1 (Mtx1) P47802 36 kDa Yes 
Translocon-associated protein 
subunit alpha (Ssr1) 
Q9CY50 32 kDa Yes 
Mitochondrial carrier homolog 1 
(Mtch1) 
Q791T5 42 kDa Yes 
1-acyl-sn-glycerol-3-phosphate 
acyltransferase delta (Agpat4) 
Q8K4X7 44 kDa Yes 
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Neuronal membrane glycoprotein 
M6-a (Gpm6a) 
P35802 31 kDa Yes 
F-box only protein 2 (Fbxo2) Q80UW2 34 kDa Yes 
Sodium/potassium-transporting 
ATPase subunit beta-3 (Atp1b3) 
P97370 32 kDa Yes 
Ephrin-A3 (Efna3) O08545 26 kDa Yes 
Cation-dependent mannose-6-
phosphate receptor (M6pr) 
P24668 31 kDa Yes 
Protein Dos (Dos) Q66L44 75 kDa Yes 
CD99 antigen-like protein 2 (Cd99l2) Q8BIF0 25 kDa Yes 
Inactive hydroxysteroid 
dehydrogenase-like protein 1 (Hsdl1) 
Q8BTX9 37 kDa Yes 
Lipid phosphate phosphatase-related 
protein type 2 (Lppr2) 
Q8VCY8 37 kDa Yes 
Isocitrate dehydrogenase [NAD] 
subunit alpha, mitochondrial (Idh3a) 
Q9D6R2 40 kDa Yes 
Myelin-oligodendrocyte glycoprotein 
(Mog) 
Q61885 28 kDa Yes 
ATP synthase subunit alpha, 
mitochondrial (Atp5a1) 
Q03265 60 kDa Yes Yes 
Cytochrome b-c1 complex subunit 2, 
mitochondrial (Uqcrc2) 
Q9DB77 48 kDa Yes Yes 
ATP synthase subunit beta, 
mitochondrial (Atp5b) 
P56480 56 kDa Yes Yes 
Tetraspanin-8 (Tspan8) Q8R3G9 26 kDa Yes 
Corticosteroid 11-beta-
dehydrogenase isozyme 1 (Hsd11b1) 
P50172 32 kDa Yes 
Retinoic acid-induced protein 3 
(Gprc5a) 
Q8BHL4 40 kDa Yes 
H-2 class II histocompatibility 
antigen, A-Q alpha chain (Fragment) 
(H2-Aa) 
P04227 24 kDa Yes 
Syntaxin-1B (Stx1b) P61264 33 kDa Yes Yes 
Ig heavy chain V region HPCG13 P01793 14 kDa Yes Yes 
Haptoglobin (Hp) Q61646 39 kDa Yes Yes 
NAD-dependent protein deacetylase 
sirtuin-2 (Sirt2) 
Q8VDQ8 43 kDa Yes Yes 
Serum albumin (Alb) P07724 69 kDa Yes Yes 
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